CoChat

Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment

Wernicke, Joachim F., Adler, Lenard, Spencer, Thomas, West, Scott A., Allen, Albert J., Heiligenstein, John, Milton, Denái, Ruff, Dustin, Brown, W. Jeffrey, Kelsey, Douglas, Michelson, David · 2004 · Journal of Clinical Psychopharmacology
Cited by 61

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Drugs that affect neurotransmitter release can induce changes in neuroregulation during chronic administration. Thus, in addition to recurrence of symptoms of the illness, discontinuation of treatment can be associated with clinical signs and symptoms related to these changes. Atomoxetine, a new drug approved in the United States for treatment of attention deficit/hyperactivity disorder (ADHD), is associated with blockade of the presynaptic norepinephrine transporter. Because treatment of ADHD typically involves chronic treatment, the potential for production of a discontinuation syndrome as well as recurrence of symptoms upon drug discontinuation were assessed as part of the clinical development process. The effects of discontinuation of atomoxetine were assessed in children and adults with ADHD following 9 to 10 weeks of continuous therapy in 4 large studies. Symptoms of ADHD worsened following drug discontinuation but did not return to pretreatment levels. The incidence of discontinuation-emergent adverse events was low and there were no statistically significant differences between the patients abruptly discontinuing from atomoxetine and those continuing on placebo. Discontinuation of atomoxetine did not result in the development of an acute discontinuation syndrome and was well tolerated. It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000104907.75206.c2

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 61

Metadata

Authors
Wernicke, J. F., Adler, L., Spencer, T., West, S. A., Allen, A. J., Heiligenstein, J., Milton, D., Ruff, D., Brown, W. J., Kelsey, D., & Michelson, D.
Venue
Journal of Clinical Psychopharmacology
Published
2004-02
Volume
24
Issue
1
Pages
30-35
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2060636676
Cited by
61
References
6
FWCI
3.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment. https://app.cochat.ai/papers/10.1097/01.jcp.0000104907.75206.c2
The paper
Wernicke, J. F., Adler, L., Spencer, T., West, S. A., Allen, A. J., Heiligenstein, J., Milton, D., Ruff, D., Brown, W. J., Kelsey, D., & Michelson, D. (2004). Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000104907.75206.c2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.